1. Clinico-Pathological Study of K-ras Mutations in Colorectal Tumors: A Single-Center Retrospective Study of 51 Patients in Madinah, Saudi Arabia
   Nasser Mulla et al, 2020, Cureus CrossRef
2. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
   T. Yoshino et al, 2018, Annals of Oncology CrossRef
3. Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer
   Jiao Yang et al, 2016, Tumor Biology CrossRef
4. Oncogenic KRAS creates an aspartate metabolism signature in colorectal cancer cells
   Peter F. Doubleday et al, 2021, The FEBS Journal CrossRef
5. Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines
   Dorna Varshavi et al, 2020, Metabolomics CrossRef
6. Selective β2‐AR Blockage Suppresses Colorectal Cancer Growth Through Regulation of EGFR‐Akt/ERK1/2 Signaling, G1‐Phase Arrest, and Apoptosis
   Chih‐Chien Chin et al, 2016, Journal of Cellular Physiology CrossRef
7. The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death
   Chiara Pozzi et al, 2016, Nature Medicine CrossRef
8. Discovery of Aberrant Alteration of Genome in Colorectal Cancer by Exome Sequencing
   Yuanzi Liang et al, 2019, The American Journal of the Medical Sciences CrossRef